Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Dezember 2025 08:30 ET | Quelle: Stemline Therapeutics, Inc.

Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early...
13. März 2017 18:07 ET | Quelle: The Rosen Law Firm PA

ALERT: Rosen Law Firm Reminds Stemline Therapeutics, Inc. Investors of Important Deadline in First Class Action Filed by Firm - STML

NEW YORK, March 13, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Stemline Therapeutics, Inc. securities (NASDAQ:STML): (1) pursuant and/or...
27. Februar 2017 18:11 ET | Quelle: The Rosen Law Firm PA

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Stemline Therapeutics, Inc. - STML

NEW YORK, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Stemline Therapeutics, Inc....